Effect of Candesartan on Microalbuminuria and Albumin Excretion Rate in Diabetes: Three Randomized Trials
Year: 2009
Type: article
Abstract: BACKGROUND: Microalbuminuria in diabetes is strongly predictive of nephropathy, end-stage renal disease, and premature cardiovascular morbidity and mortality. Effective preventive therapies are therefore a clinical priority. OBJECTIVE: To determine whether the angiotensin-receptor blocker candesartan compared with placebo affects microalbuminuria incidence or rate of change in albuminuria in type 1 and type 2 diabetes. DESIGN: 3 randomized trials of the DIRECT (Diabetic Retinopathy Candesartan Trials) Program. SETTING: 309 secondary care centers. PATIENTS: 3326 and 1905 patients with type 1 and type 2 diabetes, respectively. Most were normotensive, and all had normoalbuminuria (median urinary albumin excretion rate, 5.0 microg/min). INTERVENTION: Candesartan, 16 mg/d increasing to 32 mg/d, versus placebo. Assignment was done centrally using an interactive voice-response system. Patients, caregivers, and researchers were blinded to treatment assignment. During a median follow-up of 4.7 years, 793 patients discontinued therapy and 63 were lost to follow-up. MEASUREMENTS: Urinary albumin excretion rate, assessed annually by 2 overnight collections; if it was 20 microg/min or greater, then 2 further collections were done. The primary end point was new microalbuminuria (3 or 4 collections of urinary albumin excretion rate >or=20 microg/min). The secondary end point was rate of change in albuminuria. RESULTS: Individual and pooled results of the 3 trials showed that candesartan had little effect on risk for microalbuminuria (pooled hazard ratio, 0.95 [95% CI, 0.78 to 1.16]; P = 0.60). Pooled results showed that the annual rate of change in albuminuria was 5.53% lower (CI, 0.73% to 10.14%; P = 0.024) with candesartan than with placebo. LIMITATIONS: Investigators recruited mainly normotensive patients or patients with well-controlled hypertension who were at low overall vascular risk, which resulted in a low rate of microalbuminuria. Studies were powered for retinal and not renal end points. CONCLUSION: Candesartan, 32 mg/d, for 4.7 years did not prevent microalbuminuria in mainly normotensive patients with type 1 or type 2 diabetes.
Source: Annals of Internal Medicine
Authors: Rudy Bilous, Nish Chaturvedi, Anne Katrin Sjølie, John Fuller, Ronald Klein, Trevor Orchard, Massimo Porta, Hans-Henrik Parving
Institutions: University of Copenhagen, University of Wisconsin–Madison, Imperial College Healthcare NHS Trust, University of Pittsburgh, Aarhus University, James Cook University Hospital, Odense University Hospital, Rigshospitalet, South Tees Hospitals NHS Foundation Trust, University College London, Imperial College London, University of Turin, Newcastle University
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Keywords: candesartan, microalbuminuria, albuminuria, diabetic nephropathy, type 1 diabetes, type 2 diabetes, angiotensin receptor blockers, urinary albumin excretion rate, diabetic retinopathy, renal protection, hypertension, cardiovascular risk, end-stage renal disease, cardiovascular morbidity and mortality, normotensive subjects, treatment discontinuation
Open Access status: green
OpenAlex ID: W2054454858
